Polyisoprenylated methylated protein methyl esterase as a putative drug target for androgen-insensitive prostate cancer.
Ontology highlight
ABSTRACT: Prostate cancer (CaP) is the most frequently diagnosed cancer in US men, with an estimated 236,590 new cases and 29,720 deaths in 2013. There exists the need to identify biomarkers/therapeutic targets for the early/companion diagnosis and development of novel therapies against the recalcitrant disease. Mutation and overexpression-induced abnormal activities of polyisoprenylated proteins have been implicated in CaP. Polyisoprenylated methylated protein methyl esterase (PMPMEase) catalyses the only reversible and terminal reaction of the polyisoprenylation pathway and may promote the effects of G proteins on cell viability. In this review, the potential role of PMPMEase to serve as a new drug target for androgen-insensitive CaP was determined. Specific PMPMEase activities were found to be 3.
SUBMITTER: Poku RA
PROVIDER: S-EPMC4154947 | biostudies-literature | 2014
REPOSITORIES: biostudies-literature
ACCESS DATA